Literature DB >> 30862462

Safety and efficacy of balloon angioplasty in symptomatic intracranial stenosis: A systematic review and meta-analysis.

Keisuke Kadooka1, Niels Hagenbuch2, Vania Anagnostakou3, Anton Valavanis3, Zsolt Kulcsár3.   

Abstract

BACKGROUND AND
PURPOSE: Endovascular treatment is offered for symptomatic intracranial stenosis (ICS) when medical therapy fails. The purpose of this meta-analysis is to evaluate the risks and effectiveness of balloon angioplasty (BA) alone.
MATERIALS AND METHODS: Systematic review and meta-analysis of all available articles on BA for symptomatic ICS was conducted. Data was analyzed separately for > 70% (Group 1) and > 50% (Group 2) stenosis. The results of the Group 1 were compared with those of SAMMPRIS study to the extent possible.
RESULTS: A total of 25 studies comprising 674 patients were included. The cumulative incidence of periprocedural (within 30 days) stroke and death were 16.3% (Group 1), 7.6% (Group 2) and 11.5% (all studies). Incidence rates of ischemic stroke in the qualifying artery territory during follow-up (per 100 patient-years) were 2.0, 2.4 and 2.3, any stroke and death during follow-up were 4.4, 7.4 and 6.9, restenosis rates were 4.9, 11.5 and 8.9 respectively. While comparison of cumulative incidences of periprocedural ischemic stroke between Group 1 (13.0%) and the medical arm from SAMMPRIS study(4.4%) showed a significant difference (P = 0.008), there was no significant difference between the Group 1 and the stenting arm from SAMMPRIS study(10.7%) in the same variable.
CONCLUSION: Balloon angioplasty for stenosis of more than 70% is likely to have similar outcome comparable to the stenting arm in the SAMMPRIS study, however it presents lower rates of late ischemic events and restenosis. These data may help deciding on the endovascular method of choice in case of medical therapy failure.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; Balloon angioplasty; Intracranial stenosis; Meta analysis; Percutaneous transluminal angioplasty; Systematic review

Mesh:

Year:  2019        PMID: 30862462     DOI: 10.1016/j.neurad.2019.02.007

Source DB:  PubMed          Journal:  J Neuroradiol        ISSN: 0150-9861            Impact factor:   3.447


  5 in total

1.  Transcranial duplex ultrasound monitoring of intracranial arterial stenosis treated with ELUTAX "3" drug-eluting balloon.

Authors:  Elena Elvira Soler; Blanca Serrano Serrano; Nicolás López Hernández; Natasha Guevara Dalrymple; Sarai Moliner Castellano; Jose Ignacio Gallego León
Journal:  Interv Neuroradiol       Date:  2020-05-31       Impact factor: 1.610

2.  Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee.

Authors:  Tanya N Turan; Osama O Zaidat; Gary S Gronseth; Marc I Chimowitz; Antonio Culebras; Anthony J Furlan; Larry B Goldstein; Nestor R Gonzalez; Julius G Latorre; Steven R Messé; Thanh N Nguyen; Rajbeer S Sangha; Michael J Schneck; Aneesh B Singhal; Lawrence R Wechsler; Alejandro A Rabinstein; Mary Dolan O'Brien; Heather Silsbee; Jeffrey J Fletcher
Journal:  Neurology       Date:  2022-03-22       Impact factor: 9.910

Review 3.  Endovascular Therapy for Symptomatic Intracranial Artery Stenosis: a Systematic Review and Network Meta-analysis.

Authors:  Tao Wang; Kun Yang; Xiao Zhang; Jichang Luo; Ran Xu; Xue Wang; Yutong Yang; Xuesong Bai; Yan Ma; Yuxiang Yan; Liqun Jiao
Journal:  Transl Stroke Res       Date:  2022-02-12       Impact factor: 6.800

4.  Balloon Angioplasty vs. Stenting for Symptomatic Intracranial Arterial Stenosis.

Authors:  Yaxuan Sun; Xihua Li; Yongxia Ding; Bin Han; Jing Wang; Kun Meng; Yan Han
Journal:  Front Neurol       Date:  2022-06-14       Impact factor: 4.086

5.  Intervals of endovascular treatment for coincidental non-adjacent unruptured aneurysms in patients with symptomatic intracranial atherosclerotic stenosis.

Authors:  Hengwei Jin; Jing Wang; Xiangyu Meng; Youxiang Li; Hongwei He
Journal:  Front Neurol       Date:  2022-09-23       Impact factor: 4.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.